- |||||||||| Ventolin (albuterol) / GSK, Proventil (albuterol) / Merck (MSD), Advair HFA (salmeterol xinafoate/fluticasone propionate inhalation aerosol) / GSK
Projected Savings on Inhalers Purchased Via Mark Cuban Cost Plus Drug Company (MCCPDC) Versus Medicare Part-D (San Diego Convention Center, Area L (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1054;
Purchasing prescription drugs through MCCPDC showed substantial potential cost-savings for pulmonology directed rugs. MCCPDC could be a reasonable financial alternative for Medicare Part D spending on pulmonology drugs to reduce the financial burden of healthcare related costs.
- |||||||||| Advair HFA (salmeterol xinafoate/fluticasone propionate inhalation aerosol) / GSK
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program (clinicaltrials.gov) - Jan 29, 2019
P=N/A, N=94, Active, not recruiting,
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=300 --> 94 | Trial completion date: Sep 2018 --> Aug 2019 | Trial primary completion date: Sep 2018 --> Aug 2019
- |||||||||| Advair HFA (salmeterol xinafoate/fluticasone propionate inhalation aerosol) / GSK
Trial primary completion date: Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program (clinicaltrials.gov) - Mar 30, 2018
P=N/A, N=300, Recruiting,
Recruiting --> Active, not recruiting | N=300 --> 94 | Trial completion date: Sep 2018 --> Aug 2019 | Trial primary completion date: Sep 2018 --> Aug 2019 Trial primary completion date: Feb 2018 --> Sep 2018
- |||||||||| Advair HFA (salmeterol xinafoate/fluticasone propionate inhalation aerosol) / GSK
Trial primary completion date: Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program (clinicaltrials.gov) - Oct 13, 2017
P=N/A, N=300, Recruiting,
Trial primary completion date: Feb 2018 --> Sep 2018 Trial primary completion date: Nov 2017 --> Feb 2018
- |||||||||| Advair HFA (salmeterol xinafoate/fluticasone propionate inhalation aerosol) / GSK
Trial primary completion date: Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program (clinicaltrials.gov) - Sep 28, 2016
P=N/A, N=300, Recruiting,
Trial primary completion date: Nov 2017 --> Feb 2018 Trial primary completion date: Nov 2016 --> Nov 2017
- |||||||||| Advair HFA (salmeterol xinafoate/fluticasone propionate inhalation aerosol) / GSK
Enrollment status, Enrollment change, Trial primary completion date: Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program (clinicaltrials.gov) - Apr 1, 2016
P=N/A, N=300, Recruiting,
Trial primary completion date: Nov 2016 --> Nov 2017 Enrolling by invitation --> Recruiting | N=200 --> 300 | Trial primary completion date: Jan 2016 --> Nov 2016
- |||||||||| Advair HFA (salmeterol xinafoate/fluticasone propionate inhalation aerosol) / GSK
Trial completion, Trial primary completion date: WEUSKOP6416: Evaluating Pneumonia in Chronic Obstructive Pulmonary Disease (COPD) Subjects (clinicaltrials.gov) - Mar 11, 2015
P=N/A, N=1, Completed,
Enrolling by invitation --> Recruiting | N=200 --> 300 | Trial primary completion date: Jan 2016 --> Nov 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> May 2013
- |||||||||| Advair HFA (salmeterol xinafoate/fluticasone propionate inhalation aerosol) / GSK
Enrollment open: Uncontrolled Lower Respiratory Symptoms in the WTC Survivor Program (clinicaltrials.gov) - Mar 31, 2014
P=N/A, N=200, Recruiting,
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> May 2013 Not yet recruiting --> Recruiting
|
